These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 8265609)

  • 21. Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.
    Lusso P; Earl PL; Sironi F; Santoro F; Ripamonti C; Scarlatti G; Longhi R; Berger EA; Burastero SE
    J Virol; 2005 Jun; 79(11):6957-68. PubMed ID: 15890935
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization of a neutralizing monoclonal antibody to the external glycoprotein of HIV-1.
    Pal R; di Marzo Veronese F; Nair BC; Rahman R; Hoke G; Mumbauer SW; Sarngadharan MG
    Intervirology; 1992; 34(2):86-93. PubMed ID: 1284059
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Binding region for human immunodeficiency virus (HIV) and epitopes for HIV-blocking monoclonal antibodies of the CD4 molecule defined by site-directed mutagenesis.
    Mizukami T; Fuerst TR; Berger EA; Moss B
    Proc Natl Acad Sci U S A; 1988 Dec; 85(23):9273-7. PubMed ID: 2461565
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Structural mimicry of CD4 by a cross-reactive HIV-1 neutralizing antibody with CDR-H2 and H3 containing unique motifs.
    Prabakaran P; Gan J; Wu YQ; Zhang MY; Dimitrov DS; Ji X
    J Mol Biol; 2006 Mar; 357(1):82-99. PubMed ID: 16426633
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Increased production of human immunodeficiency virus (HIV) in HIV-induced syncytia formation: an efficient infection process.
    Chowdhury MI; Koyanagi Y; Suzuki M; Kobayashi S; Yamaguchi K; Yamamoto N
    Virus Genes; 1992 Jan; 6(1):63-78. PubMed ID: 1347963
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cross-Linking of a CD4-Mimetic Miniprotein with HIV-1 Env gp140 Alters Kinetics and Specificities of Antibody Responses against HIV-1 Env in Macaques.
    Shen X; Bogers WM; Yates NL; Ferrari G; Dey AK; Williams WT; Jaeger FH; Wiehe K; Sawant S; Alam SM; LaBranche CC; Montefiori DC; Martin L; Srivastava I; Heeney J; Barnett SW; Tomaras GD
    J Virol; 2017 Oct; 91(19):. PubMed ID: 28490585
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antibody raised against soluble CD4-rgp120 complex recognizes the CD4 moiety and blocks membrane fusion without inhibiting CD4-gp120 binding.
    Celada F; Cambiaggi C; Maccari J; Burastero S; Gregory T; Patzer E; Porter J; McDanal C; Matthews T
    J Exp Med; 1990 Oct; 172(4):1143-50. PubMed ID: 2212945
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Separation and partial characterization of proteinases with substrate specificity for basic amino acids from human MOLT-4 T lymphocytes: identification of those inhibited by variable-loop-V3 peptides of HIV-1 (human immunodeficiency virus-1) envelope glycoprotein.
    Harvima IT; Harvima RJ; Nilsson G; Ivanoff L; Schwartz LB
    Biochem J; 1993 Jun; 292 ( Pt 3)(Pt 3):711-8. PubMed ID: 8318003
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rationally Designed Immunogens Targeting HIV-1 gp120 V1V2 Induce Distinct Conformation-Specific Antibody Responses in Rabbits.
    Jiang X; Totrov M; Li W; Sampson JM; Williams C; Lu H; Wu X; Lu S; Wang S; Zolla-Pazner S; Kong XP
    J Virol; 2016 Dec; 90(24):11007-11019. PubMed ID: 27707920
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rationally Designed Vaccines Targeting the V2 Region of HIV-1 gp120 Induce a Focused, Cross-Clade-Reactive, Biologically Functional Antibody Response.
    Zolla-Pazner S; Powell R; Yahyaei S; Williams C; Jiang X; Li W; Lu S; Wang S; Upadhyay C; Hioe CE; Totrov M; Kong X
    J Virol; 2016 Dec; 90(24):10993-11006. PubMed ID: 27630234
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differences in affinity of anti-CD4 monoclonal antibodies predict their effects on syncytium induction by human immunodeficiency virus.
    Wilks D; Walker L; O'Brien J; Habeshaw J; Dalgleish A
    Immunology; 1990 Sep; 71(1):10-5. PubMed ID: 2210798
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synergistic inhibition of HIV-1 envelope-mediated cell fusion by CD4-based molecules in combination with antibodies to gp120 or gp41.
    Allaway GP; Ryder AM; Beaudry GA; Maddon PJ
    AIDS Res Hum Retroviruses; 1993 Jul; 9(7):581-7. PubMed ID: 8369162
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characterization of T cell-expressed chimeric receptors with antibody-type specificity for the CD4 binding site of HIV-1 gp120.
    Bitton N; Verrier F; Debré P; Gorochov G
    Eur J Immunol; 1998 Dec; 28(12):4177-87. PubMed ID: 9862354
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined intra- and extracellular immunization against human immunodeficiency virus type 1 infection with a human anti-gp120 antibody.
    Chen SY; Khouri Y; Bagley J; Marasco WA
    Proc Natl Acad Sci U S A; 1994 Jun; 91(13):5932-6. PubMed ID: 8016092
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Minimal sequence requirements for synthetic peptides derived from the V3 loop of the human immunodeficiency virus type 1 (HIV-1) to enhance HIV-1 binding to cells and infection.
    Zanotto C; Calderazzo F; Dettin M; Di Bello C; Autiero M; Guardiola J; Chieco-Bianchi L; De Rossi A
    Virology; 1995 Feb; 206(2):807-16. PubMed ID: 7856094
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synthetic peptides derived from the variable regions of an anti-CD4 monoclonal antibody bind to CD4 and inhibit HIV-1 promoter activation in virus-infected cells.
    Monnet C; Laune D; Laroche-Traineau J; Biard-Piechaczyk M; Briant L; Bès C; Pugnière M; Mani JC; Pau B; Cerutti M; Devauchelle G; Devaux C; Granier C; Chardès T
    J Biol Chem; 1999 Feb; 274(6):3789-96. PubMed ID: 9920932
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Class II MHC molecules and the HIV gp 120 envelope protein interact with functionally distinct regions of the CD4 molecule.
    Lamarre D; Capon DJ; Karp DR; Gregory T; Long EO; Sékaly RP
    EMBO J; 1989 Nov; 8(11):3271-7. PubMed ID: 2555159
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A monoclonal antibody to the gp120-CD4 complex has differential effect on HIV-induced syncytium formation and viral infectivity.
    Konopka K; Pretzer E; Celada F; Düzgüneş N
    J Gen Virol; 1995 Mar; 76 ( Pt 3)():669-79. PubMed ID: 7897355
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lateral diffusion of CD4 on the surface of a human neoplastic T-cell line probed with a fluorescent derivative of the envelope glycoprotein (gp120) of human immunodeficiency virus type 1 (HIV-1).
    Pal R; Nair BC; Hoke GM; Sarngadharan MG; Edidin M
    J Cell Physiol; 1991 May; 147(2):326-32. PubMed ID: 2040664
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Isolation and characterization of a novel neutralizing antibody targeting the CD4-binding site of HIV-1 gp120.
    Qiao Y; Man L; Qiu Z; Yang L; Sun Y; He Y
    Antiviral Res; 2016 Aug; 132():252-61. PubMed ID: 27387828
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.